Drug intelligence / Profile preview

oral peptide IL23R inhibitor

Development stage: Preclinical
Lead developer: AbbVie
Modality: Peptides
Administration: Oral

Overview

An investigational oral peptide IL23R inhibitor, initially developed by Nimble Therapeutics and subsequently acquired by AbbVie, is being developed for the treatment of psoriasis. This preclinical asset represents a strategic move by AbbVie to expand its immunology pipeline with novel oral therapies. The acquisition involved a $210 million upfront cash payment and potential future development milestones of up to $130 million.

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on oral peptide IL23R inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oral peptide IL23R inhibitor.

Explore the full profile